ALG3 and breast cancer: Fig. S7H showed a trend for the subgroup TP53(−) & ALG3(Low) but it was not significant for outcome after RT in the other subgroups, which was consistent with that both TP53 mutation [85] and ALG3 overexpression would significantly influence the radiosensitivity of breast cancer.